German Biotech BioNTech Locks in $270M Series A
The Company previously completed a seed round fundraising in 2008 concurrent with its founding. Source: BioSpace
Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal
Pfizer will use Arvinas' proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Source: BioSpace
OvaScience Pinks Slips Nearly 50% of Workforce
OvaScience provided a corporate update that includes initial data from a Phase I trial and news of extensive layoffs. Source: BioSpace
Neurogastrx Bags $45M, a New CEO and a HQ Move to the Greater Boston Area
The Series A financing was co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners. Source: BioSpace
Generation Bio Emerges With $25M and Former Sobi CEO as Its New Leader
Generation Bio is developing a breakthrough class of genetic medicines based on its proprietary GeneWave technology Source: BioSpace
Novartis' New Year Continues With Second FDA Breakthrough Tag of the Week
A Novartis drug approved as a second-line treatment for a blood disorder snagged the FDA's Breakthrough Therapy Designation as a first-line defense. Source: BioSpace
Indian Facility Warned for Repeat Sterility Concerns
The FDA issued a warning letter to Fresenius Kabi for GMP violations observed at its manufacturing facility in Himachal Pradesh, India, citing a failure to investigate sterility issues. Source: Drug…
Retirement Funds Sue Valeant for Billions Lost Through Price-Gouging Scheme
A group of investors sued Valeant Pharmaceuticals claiming the drugmaker cost them more than $80 billion through price-gouging. Source: Drug Industry Daily
Spark Therapeutics Proposes Value-Based Reimbursement, Installment Plans for Luxturna
Amid controversy over the high cost of its newly approved gene therapy Luxturna — $850,000 before discounts — Spark Therapeutics announced a series of initiatives to improve patient access to…
DOJ Recovered $900 Million From FCA Violators in Pharma Last Year
The Justice Department recovered more than $900 million from medical product manufacturers relating to False Claims Act violations in fiscal 2017, down from $1.2 billion in 2016. Source: Drug Industry…
- Go to the previous page
- 1
- …
- 209
- 210
- 211
- 212
- 213
- 214
- 215
- …
- 610
- Go to the next page